Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | The potential use of CAR-T therapy following autologous transplantation in multiple myeloma

Surbhi Sidana • 27 Aug 2022
IMS 2022
Multiple Myeloma CAR-T Idecabtagene vicleucel

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the possibility of using BCMA-directed CAR-T therapy following autologous transplantation in patients with multiple myeloma who do not respond well to transplantation in order to prolong remission and prevent relapse. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Surbhi Sidana

Managing toxicities associated with immunotherapy in multiple myeloma 1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Ide-cel therapy for multiple myeloma with renal impairment 1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
An overview of the toxicities associated with immunotherapy in multiple myeloma 3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Real-world outcomes of ide-cel in heavily pre-treated R/R MM 1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals